6144 POSTER Phase II Study of Panitumumab With Irinotecan for Patients With KRas Wild-type Metastatic Colorectal Cancer (MCRC) Refractory to Standard Chemotherapy – a GERCor Study

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

Standard Chemotherapy

Phase II study of panitumumab with irinotecan for patients with KRAS wild-type metastatic colorectal cancer (MCRC) refractory to standard chemotherapy: A GERCOR study.

10.1200/jco.2011.29.15_suppl.3573 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 3573-3573 ◽

Cited By ~ 2

Author(s):

B. Chibaudel ◽

C. Tournigand ◽

M. Mabro ◽

M. Bennamoun ◽

P. Artru ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

Standard Chemotherapy

Phase II Study of Cetuximab Rechallenge in Patients with RAS Wild-Type metastatic Colorectal Cancer: E-Rechallenge Trial

Annals of Oncology ◽

10.1093/annonc/mdz338.112 ◽

2019 ◽

Vol 30 ◽

pp. vi116 ◽

Cited By ~ 2

Author(s):

Masato Nakamura

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Wild Type

Phase ii study of mytomicin-c plus uft/lv in patients with metastatic colorectal cancer refractory to standard chemotherapy. subgroup analysis of predictive variables in discriminating early progressors

Annals of Oncology ◽

10.1093/annonc/mdw335.49 ◽

2016 ◽

Vol 27 ◽

pp. iv53

Author(s):

C. Sonetto ◽

C. Baratelli ◽

M.P. Brizzi ◽

M. Di Maio ◽

G.V. Scagliotti ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Subgroup Analysis ◽

Phase Ii Study ◽

Standard Chemotherapy ◽

Predictive Variables

Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G)

European Journal of Cancer ◽

10.1016/j.ejca.2020.04.014 ◽

2020 ◽

Vol 135 ◽

pp. 11-21 ◽

Cited By ~ 1

Author(s):

Daisuke Sakai ◽

Hiroya Taniguchi ◽

Naotoshi Sugimoto ◽

Takao Tamura ◽

Tomohiro Nishina ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Wild Type

Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study)

Medical Oncology ◽

10.1007/s12032-019-1254-4 ◽

2019 ◽

Vol 36 (6) ◽

Cited By ~ 1

Author(s):

Naoki Nagata ◽

Hiromichi Maeda ◽

Keiichiro Ishibashi ◽

Keiji Hirata ◽

Akitaka Makiyama ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Wild Type ◽

Open Label ◽

Randomized Phase Ii

PEAK: A randomized phase II study to compare the efficacy of panitumumab plus mFOLFOX6 to bevacizumab plus mFOLFOX6 in patients (pts) with previously untreated, unresectable metastatic colorectal cancer (mCRC) expressing wild-type KRAS.

10.1200/jco.2010.28.15_suppl.tps189 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. TPS189-TPS189

Author(s):

L. S. Schwartzberg ◽

V. J. Wagner

Keyword(s):

Colorectal Cancer ◽

Unresectable Metastatic Colorectal Cancer

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

Randomized Phase Ii ◽

Randomized phase II study of regorafenib followed by cetuximab versus reverse sequence for wild-type KRAS metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and irinotecan (REVERCE).

10.1200/jco.2014.32.15_suppl.tps3662 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS3662-TPS3662

Author(s):

Kohei Shitara ◽

Kentaro Yamazaki ◽

Hiroyuki Uetake ◽

Takeshi Kato ◽

Eiji Oki ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

Randomized Phase Ii ◽

Reverse Sequence ◽

Previously Treated

A randomized phase II study (B2151005) of the intravenous phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor PF-05212384 plus irinotecan versus cetuximab plus irinotecan in patients with wild-type KRAS metastatic colorectal cancer (mCRC).

10.1200/jco.2014.32.15_suppl.tps3649 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS3649-TPS3649 ◽

Cited By ~ 2

Author(s):

Josep Tabernero ◽

Nicoletta Brega ◽

Craig Davis ◽

Ashwin Gollerkeri ◽

Kristen Pierce ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Mtor Inhibitor ◽

Phase Ii Study ◽

Mammalian Target Of Rapamycin ◽

Target Of Rapamycin ◽

Wild Type ◽

Phosphatidylinositol 3 Kinase ◽

Randomized Phase Ii

Phase II study of cetuximab rechallenge in patients with ras wild-type metastatic colorectal cancer: E-rechallenge trial

Annals of Oncology ◽

10.1093/annonc/mdy281.029 ◽

2018 ◽

Vol 29 ◽

pp. viii161 ◽

Cited By ~ 1

Author(s):

H. Osawa ◽

E. Shinozaki ◽

M. Nakamura ◽

Y. Ohhara ◽

Y. Shindo ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Wild Type

Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition

Clinical Colorectal Cancer ◽

10.1016/j.clcc.2019.02.004 ◽

2019 ◽

Vol 18 (2) ◽

pp. 125-132.e2 ◽

Cited By ~ 8

Author(s):

Lorenza Rimassa ◽

Silvia Bozzarelli ◽

Filippo Pietrantonio ◽

Stefano Cordio ◽

Sara Lonardi ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Acquired Resistance ◽

Egfr Inhibitors ◽

Wild Type ◽

Dual Inhibition